Free tool
FAERS Monitor: Pentasa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020049 or its brand name (Pentasa, Mesalamine). Reports on generic versions are filed under their own applications.
Reports
43,912
Serious
36,874
84% of reports
Hospitalization
15,081
Death reported
2,603
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use8,661
- drug ineffective5,980
- colitis ulcerative5,816
- condition aggravated4,320
- diarrhoea3,945
- abdominal pain3,208
- fatigue3,198
- haematochezia3,172
- nausea2,748
- headache2,623
- pyrexia2,548
- weight decreased2,528
- crohn^s disease2,493
- arthralgia2,436
- frequent bowel movements2,307
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 339 |
| 2005 | 372 |
| 2006 | 354 |
| 2007 | 453 |
| 2008 | 754 |
| 2009 | 588 |
| 2010 | 688 |
| 2011 | 1,353 |
| 2012 | 1,565 |
| 2013 | 1,133 |
| 2014 | 1,274 |
| 2015 | 1,355 |
| 2016 | 1,237 |
| 2017 | 1,047 |
| 2018 | 1,385 |
| 2019 | 1,647 |
| 2020 | 2,189 |
| 2021 | 3,496 |
| 2022 | 5,122 |
| 2023 | 5,137 |
| 2024 | 4,860 |
| 2025 | 4,753 |
| 2026 | 2,809 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,010,247 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| colitis ulcerativeSignal | 5,816 | 71.5 | 69.7 | 352,357 |
| frequent bowel movementsSignal | 2,307 | 44.6 | 42.8 | 90,074 |
| haematocheziaSignal | 3,172 | 29.1 | 28.1 | 81,435 |
| condition aggravatedSignal | 4,320 | 6.9 | 6.7 | 21,749 |
| abdominal painSignal | 3,208 | 6.7 | 6.5 | 15,456 |
| off label useSignal | 8,661 | 4.8 | 4.7 | 26,700 |
| weight decreasedSignal | 2,528 | 4.4 | 4.2 | 6,590 |
| pyrexiaSignal | 2,548 | 3.5 | 3.4 | 4,698 |
| diarrhoeaSignal | 3,945 | 2.9 | 2.9 | 5,173 |
| arthralgiaSignal | 2,436 | 2.8 | 2.7 | 2,893 |
| drug ineffectiveSignal | 5,980 | 2.2 | 2.1 | 4,049 |
| headacheSignal | 2,623 | 2.0 | 1.9 | 1,362 |
| fatigue | 3,198 | 2.0 | 1.9 | 1,582 |
| nausea | 2,748 | 1.7 | 1.6 | 756 |
| crohn^s disease | 2,493 | 0.0 | 0.0 | 1,192,469 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.